TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16955042

Group type: EXPERIMENTAL
Intervention: Teleradiology (TR)
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Video Consultation (VC)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Telephone Consultation (TC)
Number of subjects: 710
Study: 15089081

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11216323

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of irrelevant information with strong relevant S-R association (arrow direction to keypress)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of irrelevant information with weak relevant S-R association (colour word to keypress)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak irrelevant colour word with 500 ms SOA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak irrelevant physical colour with 500 ms SOA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended SOAs of 3 s
Number of subjects: 0
Study: 9756188

Group type: EXPERIMENTAL
Intervention: Theophylline withdrawal for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Continued theophylline treatment (400 mg/day) for 6 weeks
Number of subjects: 38
Study: 7870401

Group type: EXPERIMENTAL
Intervention: Quantitative 67Ga-citrate lung scanning in SLE patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Quantitative 67Ga-citrate lung scanning in SLE patients with flare stage or negative chest X-ray
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal controls (20 individuals)
Number of subjects: 34
Study: 3407871

Group type: EXPERIMENTAL
Intervention: Suxamethonium 50 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Suxamethonium 15 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Suxamethonium 25 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Suxamethonium 15 mg, 25 mg, 50 mg
Number of subjects: 52
Study: 31317599

Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Individual appointments (IA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both SMA and IA
Number of subjects: 140
Study: 28341107

Group type: EXPERIMENTAL
Intervention: Epidural injection of morphine 0.1 mg kg–1 with levobupivacaine 0.5% (1 mg kg–1; group LevoBM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epidural injection of morphine 0.1 mg kg–1 with bupivacaine 0.5% (1 mg kg–1; group BM)
Number of subjects: 26
Study: 25952661

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (50 IU kg(-1) dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (single and multiple dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (age-based analysis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (ethnicity-based analysis)
Number of subjects: 0
Study: 23590463

Group type: COMPARATOR
Intervention: Stylet
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Forceps-guided tube exchanger
Number of subjects: 178
Study: 21697704

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - bilateral knee extension (10 sets of 15 repetitions with 90% of 15 repetitions maximum)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (CG) - stayed at rest
Number of subjects: 16
Study: 19473502

Group type: EXPERIMENTAL
Intervention: Clinical trials published in Acta Psychiatrica Scandinavica
Number of subjects: 582
Study: 17125500

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional open technique
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study: 15282655

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional use of GP IIb/IIIa inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study: 11142535

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE) therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-list (WL) control
Number of subjects: 49
Study: 10184722

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technologies for teaching coping skills
Number of subjects: 0
Study: 1490794

Group type: EXPERIMENTAL
Intervention: Atenolol (A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard preparation (S)
Number of subjects: 12
Study: 2579902

Group type: EXPERIMENTAL
Intervention: 12-week exercise program (45 minutes, 3-5 times per week)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 63
Study: 31171508

Group type: EXPERIMENTAL
Intervention: anthracycline and cytarabine induction chemotherapy
Number of subjects: 1884
Study: 28274173

Group type: EXPERIMENTAL
Intervention: Bakri balloon
Number of subjects: 66

Group type: COMPARATOR
Intervention: Condom-loaded Foley's catheter
Number of subjects: 66
Study: 26392328

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with omeprazole
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150 mg with rabeprazole
Number of subjects: 9
Study: 23959566

Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 74

Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fructose addition
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Glucose addition
Number of subjects: 74
Study: 21948118

Group type: EXPERIMENTAL
Intervention: Smartseal sealer and a 0.06 taper Smartpoint calibrated to apical tip size 30
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Smartseal sealer and an F3 SmartpointPT
Number of subjects: 40

Group type: COMPARATOR
Intervention: AH‐26 sealer and a single F3 ProTaper gutta‐percha cone
Number of subjects: 40

Group type: COMPARATOR
Intervention: AH‐26 sealer and gutta‐percha using the cold lateral condensation technique
Number of subjects: 40
Study: 19576090

Group type: EXPERIMENTAL
Intervention: PCT group (n = 63)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (n = 64)
Number of subjects: 127
Study: 17469884

Group type: EXPERIMENTAL
Intervention: Paroxetine (AD therapy)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 240
Study: 15669706

Group type: EXPERIMENTAL
Intervention: Three narrow‐diameter roughened‐surface implants placed in edentulous maxillas using a one‐stage surgical procedure.
Number of subjects: 40
Study: 12578902

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network Analysis (ANNA)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 178

Group type: COMPARATOR
Intervention: Partin Tables
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Best ANNA
Number of subjects: 178

Group type: COMPARATOR
Intervention: Best Logistic Regression
Number of subjects: 178
Study: 9578186

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 10

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 10
Study: 10610011

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 500 mg/day fasting
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 500 mg/day with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/day fasting
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/day with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1000 mg/day fasting
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1000 mg/day with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1500 mg/day with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg twice/day with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension with TMP-SMX
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension with food
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 1500 mg/day
Number of subjects: 22
Study: 1725026

Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: 5 mg of ramipril in combination with 20 mg of furosemide daily
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo (during run-in phase)
Number of subjects: 661
Study: 6390537

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone for patients with favorable prognostic indicators and negative staging laparotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of multiple chemotherapy and radiotherapy for patients with positive laparotomy or unfavorable prognostic indicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staging laparotomy for patients with favorable prognostic indicators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staging laparotomy for patients with unfavorable prognostic indicators
Number of subjects: 0
Study: 31215538

Group type: EXPERIMENTAL
Intervention: Cytoflavin (main group, n=53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard conservative treatment (control group, n=50)
Number of subjects: 103
Study: 29898066

Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 6% Sodium Hypochlorite (NaOCl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + 2% Chlorhexidine solution (CHXs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EndoVac (EV) + Saline solution (SS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 6% Sodium Hypochlorite (NaOCl)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 2% Chlorhexidine gel + saline solution (CHXg + SS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + 2% Chlorhexidine solution (CHXs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional irrigation (CI) + Saline solution (SS)
Number of subjects: 80
Study: 26446706

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24290979

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment for opioid dependence
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Neonates requiring pharmacotherapy for NAS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Neonates not requiring pharmacotherapy for NAS
Number of subjects: 58
Study: 22906278

Group type: EXPERIMENTAL
Intervention: Cable Pin System (CPS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tension Band Wiring (TBW)
Number of subjects: 62
Study: 20060257

Group type: EXPERIMENTAL
Intervention: Outcome expectation for exercise (OEE)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Helplessness
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Literacy
Number of subjects: 391
Study: 18084949

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodal approach involving radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidermal growth factor receptor monoclonal antibodies (EGFR‐MoABs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti‐angiogenic drugs
Number of subjects: 0
Study: 15650802

Group type: EXPERIMENTAL
Intervention: Bilateral subtotal thyroidectomy (Group A)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Unilateral total and contralateral subtotal thyroidectomy (Group B)
Number of subjects: 340
Study: 12922963

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10634923

Group type: EXPERIMENTAL
Intervention: Nutritional counseling with fortified drink supplements (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutritional counseling with normal food (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 50
Study: 7972617

Group type: EXPERIMENTAL
Intervention: Naloxone (5 mg i.v.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Contact heat
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skin sensitivity for nonnoxious stimuli (warmth, cold, vibration)
Number of subjects: 20
Study: 2784061

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 31
Study: 45539

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.8 mg sublingual
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Penbutolol 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31448846

Group type: EXPERIMENTAL
Intervention: Lofexidine (LFX) 2.4 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 57
Study: 28453452

Group type: EXPERIMENTAL
Intervention: Sensorimotor training using the HUBER exercise system for 5 weeks (10 sessions)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sensorimotor training using the HUBER exercise system
Number of subjects: 53
Study: 25770433

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: Conventional cigarette use
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: Dual use
Number of subjects: 2693
Study: 23949882

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/week, with dose escalation until serum total testosterone of 20 nmol/l)
Number of subjects: 42
Study: 20605150

Group type: EXPERIMENTAL
Intervention: External Aortic Compression Device (EACD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no EACD)
Number of subjects: 120
Study: 18068369

Group type: EXPERIMENTAL
Intervention: Stereotactic limbic leukotomy (subcaudate tractotomy and cingulotomy) via radiofrequency thermocoagulation
Number of subjects: 16
Study: 16368630

Group type: EXPERIMENTAL
Intervention: Movement imagery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stretching imagery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 12800099

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/d) for 12 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no rosiglitazone)
Number of subjects: 118
Study: 10819830

Group type: EXPERIMENTAL
Intervention: semi‐Fowler position
Number of subjects: 108

Group type: COMPARATOR
Intervention: left lateral recumbent position
Number of subjects: 108
Study: 8781766

Group type: EXPERIMENTAL
Intervention: Troglitazone (200, 400, 600, or 800 mg once daily, or 200 or 400 mg twice daily)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 and 800 mg/day)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 and 600 mg doses)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Troglitazone (highest doses)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 1311974

Group type: EXPERIMENTAL
Intervention: Methadone (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 22
Study: 3884746

Group type: EXPERIMENTAL
Intervention: cis-diamminedichloroplatinum (DDP)
Number of subjects: 135

Group type: COMPARATOR
Intervention: combination of cyclophosphamide (CTX), Adriamycin (ADR), and DDP (CAD)
Number of subjects: 135
Study: 29297769

Group type: EXPERIMENTAL
Intervention: Video visits with remote specialists
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Video visits
Number of subjects: 183
Study: 29231524

Group type: EXPERIMENTAL
Intervention: Need-in-row combined with herb-partition moxibustion
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Need-in-row therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 105
Study: 24863090

Group type: EXPERIMENTAL
Intervention: Supervised exercise training program (60 minutes of aerobic and stretching exercises, twice a week for 12 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Supervised exercise training program
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (untrained patients)
Number of subjects: 33
Study: 22038992

Group type: COMPARATOR
Intervention: 0% crude glycerol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 5% crude glycerol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 10% crude glycerol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 12.5% crude glycerol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 15% crude glycerol
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 20% crude glycerol
Number of subjects: 172
Study: 20337621

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 18407904

Group type: EXPERIMENTAL
Intervention: Protein powder supplement aiming at 36 g of protein per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Energy and protein supplements aiming at 37.6 g of protein and 500 kcal per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study: 15759528

Group type: EXPERIMENTAL
Intervention: Teaching package for nurses to improve patient positioning
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no teaching package)
Number of subjects: 120
Study: 12450709

Group type: EXPERIMENTAL
Intervention: Air drying
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Maleic acid
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Scotchbond primer
Number of subjects: 130

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 130
Study: 10071426

Group type: EXPERIMENTAL
Intervention: Group I: 240 mg CBS every 12 h for 6 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group II: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus tetracycline 500 mg every 8 h for 10 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group III: 240 mg CBS every 12 h for 6 weeks, plus metronidazole 500 mg every 8 h plus amoxicillin 750 mg every 12 h for 10 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 53
Study: 12836712

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study: 1835403

Group type: EXPERIMENTAL
Intervention: TP-1
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7174214

Group type: EXPERIMENTAL
Intervention: Physical activity programme during febrile illness
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (bed rest)
Number of subjects: 18
Study: 31560600

Group type: EXPERIMENTAL
Intervention: Training to master an artificial morphological rule (AMR) through exposure and usage; specific tasks included judgment and production tasks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training to judge and produce repeated items of the AMR.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mastering task-specific phonological regularities.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Generalization of the AMR to new items.
Number of subjects: 26
Study: 28111410

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 15 days or longer (15DL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment for 14 days or shorter (14DS)
Number of subjects: 0
Study: 26108162

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manual thrombus aspiration (MTA)
Number of subjects: 80
Study: 24197826

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) 5 ml injected into the epidural space before catheter insertion
Number of subjects: 290

Group type: COMPARATOR
Intervention: No fluid injected into the epidural space before catheter insertion (Control)
Number of subjects: 290
Study: 22067058

Group type: EXPERIMENTAL
Intervention: Immediate 2-weeks treatment group (N=28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist-control group (N=21)
Number of subjects: 49
Study: 19737980

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 51
Study: 17923489

Group type: EXPERIMENTAL
Intervention: GSK364735 (50 to 400 mg single doses, 100 to 600 mg repeated doses for 8 days)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: GSK364735
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15100560

Group type: EXPERIMENTAL
Intervention: RAP-Kiwi
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 11322666

Group type: EXPERIMENTAL
Intervention: Recognition and simple intervention for depression in old age
Number of subjects: 0
Study: 9476578

Group type: EXPERIMENTAL
Intervention: IVUS-bearing balloon catheter (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: PTCA without IVUS (group B)
Number of subjects: 42
Study: 8179044

Group type: EXPERIMENTAL
Intervention: Audio self‐administered questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written self‐administered questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face‐to‐face interviews
Number of subjects: 0
Study: 3148149

Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26